Esophagectomy in Treating Patients With High-Grade Dysplasia of the Esophagus or Stage I, Stage II, or Stage III Esophageal Cancer
This study has been completed.
Sponsor:
Eastern Cooperative Oncology Group
Collaborators:
Cancer and Leukemia Group B
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group
ClinicalTrials.gov Identifier:
NCT00063986
First received: July 8, 2003
Last updated: February 7, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Laparoscopic-assisted surgery and video-assisted thoracoscopy are less invasive types of surgery for esophageal cancer that may have fewer side effects and improve recovery.
PURPOSE: This phase II trial is studying how well laparoscopic-assisted surgery and video-assisted thoracoscopy work in treating patients who are undergoing esophagectomy for high-grade dysplasia of the esophagus or stage I, stage II, or stage III esophageal cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Esophageal Cancer |
Procedure: Minimally invasive esophagectomy (MIE) |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Minimally Invasive Esophagectomy (MIE): A Multicenter Feasibility Study |
Resource links provided by NLM:
Further study details as provided by Eastern Cooperative Oncology Group:
Primary Outcome Measures:
- Peri-operative Mortality at 30 Days [ Time Frame: Assessed at 30 days from surgery ] [ Designated as safety issue: Yes ]The primary endpoint is 30-day peri-operative mortality rate. Proportion of patients died within 30 days of surgery will be reported.
Secondary Outcome Measures:
- Rate of Conversion to Open Operation [ Time Frame: Assessed at surgery ] [ Designated as safety issue: No ]Proportion of patients who required conversion to operation will be reported.
- Duration of Operating Time [ Time Frame: Assessed at surgery ] [ Designated as safety issue: No ]The length of the operation (total of thoracic and abdominal components) is recorded.
- Duration of Intensive Care Stay [ Time Frame: Assessed after surgery until patients are out of intensive care ] [ Designated as safety issue: No ]Number of post-operative days in intensive care is reported.
- Overall Length of Hospital Stay [ Time Frame: Assessed after surgery until patients are out of hospital ] [ Designated as safety issue: No ]The number of days patients stayed in the hospital after surgery is reported.
- Total Number of Lymph Nodes Dissected [ Time Frame: Assessed at surgery ] [ Designated as safety issue: No ]The total number of lymph nodes dissected is reported to assess the effectiveness of lymph node dissection by MIE.
- 3-year Survival Rate [ Time Frame: Assessed at 3 years ] [ Designated as safety issue: No ]Patients are followed for survival for 3 years from registration. Overall survival is defined as the time from operation to death.
- 30-day Peri-operative Mortality After Neoadjuvant Therapy [ Time Frame: Assessed at 30 days after surgery ] [ Designated as safety issue: Yes ]Proportion of patients with neoadjuvant therapy died within 30 days of operation is reported.
- Rate of Conversion to Open Operation After Neoadjuvant Therapy [ Time Frame: Assessed at surgery ] [ Designated as safety issue: No ]Proportion of patients with neoadjuvant therapy required conversion to open operation is reported.
| Enrollment: | 110 |
| Study Start Date: | March 2004 |
| Study Completion Date: | August 2012 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Minimally invasive esophagectomy (MIE)
Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
|
Procedure: Minimally invasive esophagectomy (MIE)
Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
|
Detailed Description:
OBJECTIVES:
- Determine the feasibility of performing minimally invasive esophagectomy (MIE), in terms of 30-day mortality, in patients with high-grade dysplasia of the esophagus or stage I-III esophageal cancer.
- Determine the complications associated with this procedure in these patients.
- Determine the rate at which conversion to open operation is required in patients undergoing this procedure.
- Determine the length of the operation, duration of intensive care unit stay, and length of hospital stay in patients undergoing this procedure.
- Determine feasibility and conversion rate of MIE after neoadjuvant therapy.
- Assess the effectiveness of lymph node dissection by MIE by recording the total number of lymph nodes dissected.
- Assess outcomes at follow-up to three years.
OUTLINE: This is a multicenter study.
Patients undergo minimally invasive esophagectomy comprising video-assisted thoracoscopy to mobilize the thoracic esophagus in combination with laparoscopy to complete the esophagectomy and a neck incision to mobilize the cervical esophagus. Mortality at 30 days is assessed.
Patients are followed every 3 months for 2 years and then every 6 months for 1 year.
ACTUAL ACCRUAL: A total of 110 patients were accrued for this study.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
INCLUSION CRITERIA:
DISEASE CHARACTERISTICS:
- High grade dysplasia of the esophagus who would undergo esophagectomy OR esophageal cancer at stage T1-T3, N0-N1 who require esophagectomy (patients with M1 disease and/or bulky lymph node involvement were excluded).
- Pathological confirmation of a diagnosis of cancer or high-grade dysplasia of the esophagus by biopsy.
- Computerized tomography (CT) scan of chest and abdomen within 6 weeks prior to registration
- Stomach must be available for conduit
- Age of 18 and over
- ECOG performance status of 0-2
- Creatinine less than 2 mg/dL
- Patients with esophageal cancer who would be treated with neoadjuvant chemotherapy and/or radiation were eligible. If patients were registered prior to receiving neoadjuvant chemotherapy they were allowed up to 5 months to complete therapy and any restaging that was necessary before operation was performed.
The patient was considered an appropriate candidate for surgery based on preoperative clinical staging and physiological factors prior to registration as documented in the surgical plan. Pre-operative staging should include:
- Endoscopic ultrasound (EUS)
- Positron emission tomography (PET) scan and/or laparoscopic staging (Laparoscopic staging could be performed on the day of resection. Additional evaluation was recommended if the PET scan suggested distant metastatic disease.)
EXCLUSION CRITERIA:
- Cancer extending into the stomach more than 20%
- Prior anti-reflux or gastric operations
- Prior right thoracotomy
- Prior major neck operation other than the removal of superficial skin lesion
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00063986
Hide Study Locations
Hide Study LocationsLocations
| United States, California | |
| Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center | |
| Orange, California, United States, 92868 | |
| United States, Georgia | |
| Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center | |
| Savannah, Georgia, United States, 31403-3089 | |
| United States, Illinois | |
| Robert H. Lurie Comprehensive Cancer Center at Northwestern University | |
| Chicago, Illinois, United States, 60611-3013 | |
| University of Chicago Cancer Research Center | |
| Chicago, Illinois, United States, 60637-1470 | |
| United States, Massachusetts | |
| Boston University Cancer Research Center | |
| Boston, Massachusetts, United States, 02118 | |
| United States, Minnesota | |
| Hutchinson Area Health Care | |
| Hutchinson, Minnesota, United States, 55350 | |
| Meeker County Memorial Hospital | |
| Lichfield, Minnesota, United States, 55355 | |
| HealthEast Cancer Care at St. John's Hospital | |
| Maplewood, Minnesota, United States, 55109 | |
| Hennepin County Medical Center - Minneapolis | |
| Minneapolis, Minnesota, United States, 55415 | |
| Masonic Cancer Center at University of Minnesota | |
| Minneapolis, Minnesota, United States, 55455 | |
| Virginia Piper Cancer Institute at Abbott - Northwestern Hospital | |
| Minneapolis, Minnesota, United States, 55407 | |
| HealthEast Cancer Care at St. Joseph's Hospital | |
| Saint Paul, Minnesota, United States, 55102 | |
| St. Francis Cancer Center at St. Francis Medical Center | |
| Shakopee, Minnesota, United States, 55379 | |
| Regions Hospital Cancer Care Center | |
| St. Paul, Minnesota, United States, 55101 | |
| HealthEast Cancer Care at Woodwinds Health Campus | |
| Woodbury, Minnesota, United States, 55125 | |
| United States, Nebraska | |
| Alegant Health Cancer Center at Bergan Mercy Medical Center | |
| Omaha, Nebraska, United States, 68124 | |
| CCOP - Missouri Valley Cancer Consortium | |
| Omaha, Nebraska, United States, 68106 | |
| Creighton University Medical Center | |
| Omaha, Nebraska, United States, 68131-2197 | |
| Immanuel Medical Center | |
| Omaha, Nebraska, United States, 68122 | |
| United States, New York | |
| Mount Sinai Medical Center | |
| New York, New York, United States, 10029 | |
| United States, Ohio | |
| Mary Rutan Hospital | |
| Bellefontaine, Ohio, United States, 43311 | |
| Adena Regional Medical Center | |
| Chillicothe, Ohio, United States, 45601 | |
| CCOP - Columbus | |
| Columbus, Ohio, United States, 43215 | |
| Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center | |
| Columbus, Ohio, United States, 43210-1240 | |
| Doctors Hospital at Ohio Health | |
| Columbus, Ohio, United States, 43228 | |
| Mount Carmel Health - West Hospital | |
| Columbus, Ohio, United States, 43222 | |
| Grant Medical Center Cancer Care | |
| Columbus, Ohio, United States, 43215 | |
| Riverside Methodist Hospital Cancer Care | |
| Columbus, Ohio, United States, 43214-3998 | |
| Grady Memorial Hospital | |
| Delaware, Ohio, United States, 43015 | |
| Fairfield Medical Center | |
| Lancaster, Ohio, United States, 43130 | |
| Strecker Cancer Center at Marietta Memorial Hospital | |
| Marietta, Ohio, United States, 45750 | |
| Licking Memorial Cancer Care Program at Licking Memorial Hospital | |
| Newark, Ohio, United States, 43055 | |
| Community Hospital of Springfield and Clark County | |
| Springfield, Ohio, United States, 45505 | |
| Mercy Medical Center | |
| Springfield, Ohio, United States, 45504 | |
| Mount Carmel St. Ann's Cancer Center | |
| Westerville, Ohio, United States, 43081 | |
| Genesis - Good Samaritan Hospital | |
| Zanesville, Ohio, United States, 43701 | |
| United States, Pennsylvania | |
| Geisinger Cancer Institute at Geisinger Health | |
| Danville, Pennsylvania, United States, 17822-0001 | |
| UPMC Cancer Centers | |
| Pittsburgh, Pennsylvania, United States, 15232 | |
| Geisinger Medical Group - Scenery Park | |
| State College, Pennsylvania, United States, 16801 | |
| Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center | |
| Wilkes-Barre, Pennsylvania, United States, 18711 | |
| United States, Texas | |
| Medical City Dallas Hospital | |
| Dallas, Texas, United States, 75230 | |
Sponsors and Collaborators
Eastern Cooperative Oncology Group
Cancer and Leukemia Group B
Investigators
| Study Chair: | James D. Luketich, MD | University of Pittsburgh |
More Information
Additional Information:
No publications provided
| Responsible Party: | Eastern Cooperative Oncology Group |
| ClinicalTrials.gov Identifier: | NCT00063986 History of Changes |
| Other Study ID Numbers: | CDR0000305866, U10CA021115, E2202 |
| Study First Received: | July 8, 2003 |
| Results First Received: | November 29, 2012 |
| Last Updated: | February 7, 2013 |
| Health Authority: | United States: Federal Government |
Keywords provided by Eastern Cooperative Oncology Group:
|
esophageal cancer minimally invasive esophagectomy (MIE) |
Additional relevant MeSH terms:
|
Esophageal Diseases Esophageal Neoplasms Gastrointestinal Diseases Digestive System Diseases Gastrointestinal Neoplasms |
Digestive System Neoplasms Neoplasms by Site Neoplasms Head and Neck Neoplasms |
ClinicalTrials.gov processed this record on May 22, 2013